When did Neurocrine Biosciences report Q4 2024 earnings?

Neurocrine Biosciences (NBIX) reported Q4 2024 earnings on February 6, 2025 after market close.

What were Neurocrine Biosciences's Q4 2024 revenue and EPS?

Neurocrine Biosciences reported revenue of $627.7M and diluted EPS of $1.00 for Q4 2024.

Did Neurocrine Biosciences beat estimates in Q4 2024?

Revenue missed the consensus estimate of $629.4M by $1.7M. EPS missed the consensus estimate of $1.62 by $0.62.

Where can I find Neurocrine Biosciences's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000914475-25-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.

Neurocrine Biosciences NBIX Q4 2024 Annual earnings

Reported February 6, 2025 · After market close

Revenue$627.7MMiss by $1.7M Diluted EPS$1.00Miss by $0.62

Revenue estimate$629.4M

EPS estimate$1.62

Next report

Jul 30, 2026 (In 2 days)

Revenue estimate$890.0M

EPS estimate$1.64

Financials

Q4 2024

Income statement

See full

Revenue$627.7M+21.8%

Gross profit$618.4M+22.0%

Operating income$142.0M-5.5%

Net income$103.1M-30.2%

EPS (diluted)$1.00-31.5%

Balance sheet

See full

Cash & equivalents$241.0M-7.0%

Total debt$495.7M+7.7%

Total equity$2.6B+16.0%

Total assets$3.7B+14.4%

Cash flow

See full

Operating cash flow$242.5M+96.4%

CapEx$7.3M+35.2%

Free cash flow$235.2M+99.2%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$13.82B+6.6%

Enterprise value$14.07B+6.9%

P/E40.5×-11.4×

P/S5.9×-1.0×

Profitability

See full

Gross margin98.6%+0.7pp

Operating margin24.2%+10.9pp

Net margin14.5%+1.3pp

FCF margin23.7%+4.5pp

Returns & leverage

See full

Return on equity14.2%+1.5pp

Debt / equity0.2×0.0×

Current ratio3.4×+0.9×

Segments

By segment

See full

Reportable Segment$627.7M+33.1%

By product

See full

Collaboration revenues$6.5M-18.8%

Versus estimates

Revenue

Q1 2026$814.5MBeat by $46.2M Q4 2025$805.5MBeat by $15.0M Q3 2025$794.9MMiss by $11.9M Q2 2025$687.5MMiss by $58.9M Q1 2025$572.6MBeat by $13.0M

Q4 2024$627.7MMiss by $1.7M

Diluted EPS

Q1 2026$1.94Beat by $0.66 Q4 2025$1.88Beat by $0.08 Q3 2025$2.04Beat by $0.46 Q2 2025$1.06Beat by $0.08 Q1 2025$0.08Miss by $0.46

Q4 2024$1.00Miss by $0.62

Ask the moment Neurocrine Biosciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Neurocrine Biosciences report Q4 2024 earnings?: Neurocrine Biosciences (NBIX) reported Q4 2024 earnings on February 6, 2025 after market close.
What were Neurocrine Biosciences's Q4 2024 revenue and EPS?: Neurocrine Biosciences reported revenue of $627.7M and diluted EPS of $1.00 for Q4 2024.
Did Neurocrine Biosciences beat estimates in Q4 2024?: Revenue missed the consensus estimate of $629.4M by $1.7M. EPS missed the consensus estimate of $1.62 by $0.62.
Where can I find Neurocrine Biosciences's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000914475-25-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.